Herceptin resistance in HER2-moderately expressed breast cancer
<p>HER2 overexpression occurs in approximately 15-20% of all breast cancers and is associated with poor prognosis. The development of Herceptin, a monoclonal antibody against HER2, has been significant in prolonging survival of these patients. Herceptin is less efficient in patients who do not...
| Prif Awduron: | , |
|---|---|
| Awduron Eraill: | |
| Fformat: | Traethawd Ymchwil |
| Iaith: | English |
| Cyhoeddwyd: |
2012
|
| Pynciau: |